Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas

University Hospital Center (CHU)

Status: Completed

Conditions: Lymphoma, B-Cell

Study type: Observational

Funder types: Other

Identifiers

NCT05133505

RECHMPL21_0665

Details and patient eligibility

About

Primary central nervous system diffuse large B cell lymphoma is a rare and aggressive entity of diffuse large B cell lymphoma. A previous transcriptomic study showed an overexpression of TIM-3 and Gal-9 in the tumor microenvironment. The investigators aimed to characterise TIM-3/Gal-9 immune checkpoints by using immunohistochemistry in the tumor microenvironment of primary central nervous system diffuse large B cell lymphoma.

Enrollment: 65 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient with a Diagnosis of LBDGC-SNC

Exclusion criteria

• immunocompromised patients
• patients with a history of previous or associated low-grade lymphoma
• patients with a history of systemic LBDGC with secondary localization to the SNC